BMO Capital analyst Matt Borsch raised his price target on Universal Health to $146, citing its above-consensus outlook for 2019 announced last week. The analyst states that while the company remains “reliant on continued acute-care strength”, the forecast has given him a better “view of expectations now that management has backed away from promises of near-term improvement in the behavioral side, which should strengthen its credibility.” Borsch is keeping his Market Perform rating on Universal Health however, noting that its current valuation of enterprise value to EBITDA at 9.1-times is “fair” and implies only modest stock price upside.
https://thefly.com/landingPageNews.php?id=2874429
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.